Cargando…

Fecal Carriage of Extended-Spectrum β-Lactamase and Carbapenemase-Producing Enterobacteriaceae Among Oncology and Non-Oncology Patients at Jimma Medical Center in Ethiopia: A Comparative Cross-Sectional Study

PURPOSE: Extended-spectrum β-lactamase (ESBL) and carbapenemase-producing Enterobacteriaceae (CPE) are among the major threats to global health because of their encoded protection against key antibiotics. METHODS: A comparative cross-sectional study was conducted among oncology and non-oncology pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Temsegen, Wubalech, Gorems, Kasahun, Mekonnen, Mekidim, Fufa, Diriba, Kassa, Tesfaye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625765/
https://www.ncbi.nlm.nih.gov/pubmed/37933318
http://dx.doi.org/10.2147/CMAR.S422376
_version_ 1785131202221441024
author Temsegen, Wubalech
Gorems, Kasahun
Mekonnen, Mekidim
Fufa, Diriba
Kassa, Tesfaye
author_facet Temsegen, Wubalech
Gorems, Kasahun
Mekonnen, Mekidim
Fufa, Diriba
Kassa, Tesfaye
author_sort Temsegen, Wubalech
collection PubMed
description PURPOSE: Extended-spectrum β-lactamase (ESBL) and carbapenemase-producing Enterobacteriaceae (CPE) are among the major threats to global health because of their encoded protection against key antibiotics. METHODS: A comparative cross-sectional study was conducted among oncology and non-oncology patient groups (1:1; n = 214) on a consecutive sampling approach. Stool or rectal swab was collected from June 2021 to November 2021 and screened for ESBL-PE and CPE using ChromID-ESBL media. Confirmation for the enzymes was made by using combination disc and modified carbapenem inactivation methods, respectively. Disk diffusion method was used to determine antimicrobial susceptibility testing following the recommendations of CLSI 2022. SPSS software version 23 was used for data analysis. RESULTS: Fecal carriage prevalence of ESBL-PE was found in 90 (84.1%) of oncology participants and in 77 (71.9%) of non-oncology patients (p = 0.032). Escherichia coli was the most common ESBL-PE isolate in 82 (62.5%) and 68 (88.3%) of oncology and non-oncology patients, followed by Klebsiella oxytoca [15 (11.5%) versus 6 (7.8%)], respectively. Out of the total ESBL-PE isolates from both oncology and non-oncology patient groups, the maximum level of resistance was observed against ciprofloxacin 177 (86.3%), trimethoprim-sulfamethoxazole 103 (80.3%), tetracycline 97 (75.8%), whereas enhanced susceptibility was appreciated to tigecycline 200 (97.6%), meropenem 162 (79.0%), and ertapenem 145 (70.7%) with no significant difference between oncology and non-oncology group. Carbapenemase-producing isolates from oncology patients were 12 (11.2%), whereas it was 4 (3.7%) (p = 0.611) from non-oncology group. Bacterial isolates from oncology in this study showed a trend of multiple drug resistance of 113 (88.3%). CONCLUSION: The results revealed alarmingly high carriage rates of ESBL and CPE among all study participants. Moreover, the isolates showed increased resistance rates to alternative drugs and had multiple antibiotic-resistant patterns. Hence, it is important to emphasize strict adherence to antimicrobial stewardship program as well as infection prevention and control practices.
format Online
Article
Text
id pubmed-10625765
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-106257652023-11-06 Fecal Carriage of Extended-Spectrum β-Lactamase and Carbapenemase-Producing Enterobacteriaceae Among Oncology and Non-Oncology Patients at Jimma Medical Center in Ethiopia: A Comparative Cross-Sectional Study Temsegen, Wubalech Gorems, Kasahun Mekonnen, Mekidim Fufa, Diriba Kassa, Tesfaye Cancer Manag Res Original Research PURPOSE: Extended-spectrum β-lactamase (ESBL) and carbapenemase-producing Enterobacteriaceae (CPE) are among the major threats to global health because of their encoded protection against key antibiotics. METHODS: A comparative cross-sectional study was conducted among oncology and non-oncology patient groups (1:1; n = 214) on a consecutive sampling approach. Stool or rectal swab was collected from June 2021 to November 2021 and screened for ESBL-PE and CPE using ChromID-ESBL media. Confirmation for the enzymes was made by using combination disc and modified carbapenem inactivation methods, respectively. Disk diffusion method was used to determine antimicrobial susceptibility testing following the recommendations of CLSI 2022. SPSS software version 23 was used for data analysis. RESULTS: Fecal carriage prevalence of ESBL-PE was found in 90 (84.1%) of oncology participants and in 77 (71.9%) of non-oncology patients (p = 0.032). Escherichia coli was the most common ESBL-PE isolate in 82 (62.5%) and 68 (88.3%) of oncology and non-oncology patients, followed by Klebsiella oxytoca [15 (11.5%) versus 6 (7.8%)], respectively. Out of the total ESBL-PE isolates from both oncology and non-oncology patient groups, the maximum level of resistance was observed against ciprofloxacin 177 (86.3%), trimethoprim-sulfamethoxazole 103 (80.3%), tetracycline 97 (75.8%), whereas enhanced susceptibility was appreciated to tigecycline 200 (97.6%), meropenem 162 (79.0%), and ertapenem 145 (70.7%) with no significant difference between oncology and non-oncology group. Carbapenemase-producing isolates from oncology patients were 12 (11.2%), whereas it was 4 (3.7%) (p = 0.611) from non-oncology group. Bacterial isolates from oncology in this study showed a trend of multiple drug resistance of 113 (88.3%). CONCLUSION: The results revealed alarmingly high carriage rates of ESBL and CPE among all study participants. Moreover, the isolates showed increased resistance rates to alternative drugs and had multiple antibiotic-resistant patterns. Hence, it is important to emphasize strict adherence to antimicrobial stewardship program as well as infection prevention and control practices. Dove 2023-11-01 /pmc/articles/PMC10625765/ /pubmed/37933318 http://dx.doi.org/10.2147/CMAR.S422376 Text en © 2023 Temsegen et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Temsegen, Wubalech
Gorems, Kasahun
Mekonnen, Mekidim
Fufa, Diriba
Kassa, Tesfaye
Fecal Carriage of Extended-Spectrum β-Lactamase and Carbapenemase-Producing Enterobacteriaceae Among Oncology and Non-Oncology Patients at Jimma Medical Center in Ethiopia: A Comparative Cross-Sectional Study
title Fecal Carriage of Extended-Spectrum β-Lactamase and Carbapenemase-Producing Enterobacteriaceae Among Oncology and Non-Oncology Patients at Jimma Medical Center in Ethiopia: A Comparative Cross-Sectional Study
title_full Fecal Carriage of Extended-Spectrum β-Lactamase and Carbapenemase-Producing Enterobacteriaceae Among Oncology and Non-Oncology Patients at Jimma Medical Center in Ethiopia: A Comparative Cross-Sectional Study
title_fullStr Fecal Carriage of Extended-Spectrum β-Lactamase and Carbapenemase-Producing Enterobacteriaceae Among Oncology and Non-Oncology Patients at Jimma Medical Center in Ethiopia: A Comparative Cross-Sectional Study
title_full_unstemmed Fecal Carriage of Extended-Spectrum β-Lactamase and Carbapenemase-Producing Enterobacteriaceae Among Oncology and Non-Oncology Patients at Jimma Medical Center in Ethiopia: A Comparative Cross-Sectional Study
title_short Fecal Carriage of Extended-Spectrum β-Lactamase and Carbapenemase-Producing Enterobacteriaceae Among Oncology and Non-Oncology Patients at Jimma Medical Center in Ethiopia: A Comparative Cross-Sectional Study
title_sort fecal carriage of extended-spectrum β-lactamase and carbapenemase-producing enterobacteriaceae among oncology and non-oncology patients at jimma medical center in ethiopia: a comparative cross-sectional study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625765/
https://www.ncbi.nlm.nih.gov/pubmed/37933318
http://dx.doi.org/10.2147/CMAR.S422376
work_keys_str_mv AT temsegenwubalech fecalcarriageofextendedspectrumblactamaseandcarbapenemaseproducingenterobacteriaceaeamongoncologyandnononcologypatientsatjimmamedicalcenterinethiopiaacomparativecrosssectionalstudy
AT goremskasahun fecalcarriageofextendedspectrumblactamaseandcarbapenemaseproducingenterobacteriaceaeamongoncologyandnononcologypatientsatjimmamedicalcenterinethiopiaacomparativecrosssectionalstudy
AT mekonnenmekidim fecalcarriageofextendedspectrumblactamaseandcarbapenemaseproducingenterobacteriaceaeamongoncologyandnononcologypatientsatjimmamedicalcenterinethiopiaacomparativecrosssectionalstudy
AT fufadiriba fecalcarriageofextendedspectrumblactamaseandcarbapenemaseproducingenterobacteriaceaeamongoncologyandnononcologypatientsatjimmamedicalcenterinethiopiaacomparativecrosssectionalstudy
AT kassatesfaye fecalcarriageofextendedspectrumblactamaseandcarbapenemaseproducingenterobacteriaceaeamongoncologyandnononcologypatientsatjimmamedicalcenterinethiopiaacomparativecrosssectionalstudy